Ipca Labs enters into technology transfer agreement with Omexa Formulary

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-29T15:23:49+05:30 | Updated On 29 March 2024 3:27 PM IST

Mumbai: lpca Laboratories Ltd. has entered into a Technology Transfer Agreement with Omexa Formulary Pvt. Ltd. for a biosimilar clone, process development and knowledge transfer for the global market.

Under this Agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market a anti-cancer biosimilar for global market.

This Agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.

Commenting on this Agreement, Pranay Godha, Managing Director and CEO, lpca Laboratories said, "This collaboration with Omexa Formulary, an innovation driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development. This collaboration with Omexa in turn shall also help lpca in the development and delivery of affordable and quality biologic medication for the treatment of chronic illnesses in the global market - a presently unmet and crucial clinical need. lpca is committed to successfully develop quality and affordable biosimilars meeting global standards and gain a decisive edge in the battle against chronic ailments."

Commenting on this Agreement Dr. Nate Ramanathan, Managing Director & CEO of Omexa Formulary said, "This collaboration with lpca, a most reliable and trusted pharmaceutical company shall facilitate Omexa the availability of expertise and technology for the biosimilars development work and ensuring that Omexa play its part in serving our core values of affordable access to quality biologic drugs for a large population through our pioneering methods in R&D and manufacturing development.

Established in 1949, lpca is a pharmaceutical company. lpca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, lpca has been a crucial healthcare partner in over 120 countries across the globe. lpca markets its branded formulations in India and rest of the world markets and generic formulations in United States, Europe, United Kingdom, Canada, Australia & New Zealand. APls manufactured by lpca are marketed across the globe. lpca has leading brands in pain, rheumatology, anti-malarials and hair care therapy and 5 of its brands rank amongst the top 300 brands (IQVIA December 2023).

ipca labsipca labs newsomexa formulary

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751